Le Lézard
Classified in: Health, Covid-19 virus
Subjects: BLK, TRI

UCLA Begins Recruitment For Phase 3 Of The Oxford University - AstraZeneca COVID-19 Vaccine Trial

LOS ANGELES, Oct. 29, 2020 /PRNewswire/ -- Recruitment is underway for volunteers for the phase 3 trial of the Oxford University ? AstraZeneca COVID-19 vaccine at UCLA Health which joins other medical centers nationwide as part of the study effort .

The vaccine, developed by Oxford University and AstraZeneca, is called AZD1222 and has successfully gone through earlier smaller phase 1 and 2 trials. The phase 3 trial is designed to determine whether two doses of the vaccine can prevent symptomatic COVID-19. The study aims to enroll 30,000 volunteers across the United States and more than 250 at UCLA. 

This vaccine does not contain a live SARS-CoV-2 virus and cannot give a person COVID-19. If the results from the trial are positive, the vaccine could be made available to the public to prevent disease. 

Recruitment for the trial has resumed following a brief pause after the FDA, the independent Data and Safety Monitoring Board, and AstraZeneca reviewed a possible adverse reaction seen in a trial participant in the United Kingdom. The FDA and independent regulators reviewed all safety data from trials globally (around 18,000 participants) and concluded it is safe to resume the phase 3 trial. It is not unusual that in large scale phase 3 trials, some participants will become unwell, and every case has to be evaluated to ensure the careful assessment of safety.  

"The safety of our volunteers and participants is the first priority of everyone working on this trial across the nation and locally here in Los Angeles," said Dr. Raphael Landovitz, the trial's lead researcher at UCLA and co-director of UCLA's Center for HIV Identification, Prevention and Treatment Services.  "Having a safe and effective vaccine is critical to ending the pandemic. We are looking forward to getting this trial underway so that we can find a vaccine for everyone, and especially those that have been most impacted by COVID-19. Help Stop COVID LA is an opportunity for the Los Angeles community to be a part of the solution to help end this pandemic.  We hope everyone who is at risk for COVID-19 or its complications will consider if volunteering for this trial is right for them."

To be eligible, a volunteer cannot have previously tested positive for COVID-19. Volunteers are assigned at random to receive the investigational vaccine or a placebo (saline injection). The trial is blinded, meaning the participants and the investigators will not know who receives the vaccine. Of the volunteers enrolled, two-thirds will get the study vaccine and one-third will get a placebo or harmless injection. This allows researchers to compare outcomes in the vaccine group against the placebo group. In the two years that follow, researchers will monitor all study volunteers for the development of symptomatic COVID-19 and for any side effects of the vaccine.

UCLA is part of the COVID-19 Prevention Network (CoVPN) participating in the phase 3 trial. The network, supported by the National Institute of Allergy and Infectious Diseases (NIAID), aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.

UCLA is recruiting volunteers who reside in the greater Los Angeles area, primarily including members of the Black, Latinx, Asian/Pacific Islander, and Native American communities that have been disproportionately affected by COVID-19 and are at  high-risk for severe disease. This also includes:

To find out more and sign up to volunteer please visit www.helpstopcovid.la


These press releases may also interest you

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 15:05
ImmunoGen Inc. , a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new safety and efficacy findings from the expansion phase of the Phase 1/2 study of IMGN632 in patients with...

at 15:00
Amgen today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily pre-treated patients with relapsed/refractory multiple myeloma (R/R MM). AMG 701 is an investigational half-life extended...

at 14:09
The Correctional Service of Canada (CSC) has over 4500 volunteers who dedicate their time and energy to work with and support the offenders in our care and custody. As we mark International Volunteer Day, CSC would like to take this opportunity to...

at 12:46
Three studies being presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to-treat blood disorders and cancers....

News published on 29 october 2020 at 15:01 and distributed by: